1. Home
  2. WEST vs CBIO Comparison

WEST vs CBIO Comparison

Compare WEST & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Westrock Coffee Company

WEST

Westrock Coffee Company

N/A

Current Price

$3.85

Market Cap

375.7M

ML Signal

N/A

CBIO

Crescent Biopharma Inc.

N/A

Current Price

$13.35

Market Cap

340.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
WEST
CBIO
Founded
2009
2003
Country
United States
United States
Employees
1408
44
Industry
Beverages (Production/Distribution)
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
375.7M
340.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
WEST
CBIO
Price
$3.85
$13.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$8.00
$26.67
AVG Volume (30 Days)
373.9K
160.9K
Earning Date
03-10-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.19
N/A
Revenue Next Year
$10.74
$355.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.59
$8.72
52 Week High
$7.92
$17.39

Technical Indicators

Market Signals
Indicator
WEST
CBIO
Relative Strength Index (RSI) 35.56 61.03
Support Level $3.62 $11.88
Resistance Level $4.69 $13.36
Average True Range (ATR) 0.25 1.01
MACD -0.02 0.18
Stochastic Oscillator 8.63 82.17

Price Performance

Historical Comparison
WEST
CBIO

About WEST Westrock Coffee Company

Westrock Coffee Co is an integrated coffee, tea, flavors, extracts, and ingredients solutions provider in the U.S, providing coffee sourcing, supply chain management, product development, roasting, packaging, and distribution services to retail, foodservice and restaurant, convenience store and travel center, non-commercial account, CPG, and hospitality industries around the world. The company's segment includes Beverage Solutions and Sustainable Sourcing and Traceability. It generates maximum revenue from the Beverage Solutions segment.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: